Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.

Preusser M, Streubel B, Berghoff AS, Hainfellner JA, von Deimling A, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, Zielinski C, Birner P.

Histopathology. 2014 Nov;65(5):684-92. doi: 10.1111/his.12475. Epub 2014 Aug 5.

PMID:
25039982
2.

High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.

Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, von Deimling A, Streubel B, Birner P.

Lung Cancer. 2014 Jan;83(1):83-9. doi: 10.1016/j.lungcan.2013.10.004. Epub 2013 Oct 17.

PMID:
24183471
3.

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).

Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.

J Thorac Oncol. 2009 Jan;4(1):12-21. doi: 10.1097/JTO.0b013e3181913e28.

4.

Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.

Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan B, Kennedy C, O'Toole SA, Cooper WA.

Clin Lung Cancer. 2016 Jan;17(1):30-8.e1. doi: 10.1016/j.cllc.2015.08.002. Epub 2015 Aug 18.

PMID:
26395411
5.

Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.

Schiefer AI, Mesteri I, Berghoff AS, Haitel A, Schmidinger M, Preusser M, Birner P.

Histopathology. 2015 Dec;67(6):799-805. doi: 10.1111/his.12709. Epub 2015 Jun 7.

PMID:
25847631
6.

Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.

Pelosi G, Del Curto B, Dell'Orto P, Pasini F, Veronesi G, Spaggiari L, Maisonneuve P, Iannucci A, Terzi A, Lonardoni A, Viale G.

Int J Cancer. 2005 Jan 1;113(1):101-8.

7.

MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.

Song Z, Wang X, Zheng Y, Su H, Zhang Y.

Clin Lung Cancer. 2017 Mar;18(2):213-219.e2. doi: 10.1016/j.cllc.2016.09.011. Epub 2016 Oct 5.

PMID:
28322191
8.

Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.

Salido M, Pijuan L, Martínez-Avilés L, Galván AB, Cañadas I, Rovira A, Zanui M, Martínez A, Longarón R, Sole F, Serrano S, Bellosillo B, Wynes MW, Albanell J, Hirsch FR, Arriola E.

J Thorac Oncol. 2011 Jan;6(1):21-7. doi: 10.1097/JTO.0b013e3181fb7cd6.

9.

ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.

Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, Schoppmann SF, Zielinski CC, Streubel B, Birner P.

Lung Cancer. 2013 Jun;80(3):278-83. doi: 10.1016/j.lungcan.2013.01.019. Epub 2013 Feb 27.

PMID:
23453647
10.

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.

Kim H, Yoo SB, Choe JY, Paik JH, Xu X, Nitta H, Zhang W, Grogan TM, Lee CT, Jheon S, Chung JH.

J Thorac Oncol. 2011 Aug;6(8):1359-66. doi: 10.1097/JTO.0b013e31821cfc73.

11.

Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma.

Mesteri I, Schoppmann SF, Preusser M, Birner P.

Eur J Cancer. 2014 May;50(7):1354-60. doi: 10.1016/j.ejca.2014.01.022. Epub 2014 Feb 21.

PMID:
24565853
12.

c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.

Tsuta K, Kozu Y, Mimae T, Yoshida A, Kohno T, Sekine I, Tamura T, Asamura H, Furuta K, Tsuda H.

J Thorac Oncol. 2012 Feb;7(2):331-9. doi: 10.1097/JTO.0b013e318241655f.

13.

Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.

Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, Konopa K, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR.

J Thorac Oncol. 2012 Feb;7(2):340-7. doi: 10.1097/JTO.0b013e318240ca0d.

14.

MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.

Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R.

Clin Cancer Res. 2015 Feb 15;21(4):907-15. doi: 10.1158/1078-0432.CCR-14-0450. Epub 2014 Dec 9.

15.

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.

Go H, Jeon YK, Park HJ, Sung SW, Seo JW, Chung DH.

J Thorac Oncol. 2010 Mar;5(3):305-13. doi: 10.1097/JTO.0b013e3181ce3d1d.

16.

Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma.

Ritter JH, Dresler CM, Wick MR.

Hum Pathol. 1995 Nov;26(11):1227-32.

PMID:
7590697
17.

Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.

He LR, Ma NF, Chen JW, Li BK, Guan XY, Liu MZ, Xie D.

Oncotarget. 2015 Oct 13;6(31):31181-90. doi: 10.18632/oncotarget.5070.

18.

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

Watermann I, Schmitt B, Stellmacher F, Müller J, Gaber R, Kugler Ch, Reinmuth N, Huber RM, Thomas M, Zabel P, Rabe KF, Jonigk D, Warth A, Vollmer E, Reck M, Goldmann T.

Diagn Pathol. 2015 Jul 28;10:130. doi: 10.1186/s13000-015-0362-5.

19.

Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.

Zhang N, Xie F, Gao W, Yu S, Qiu L, Lin W, Sun Y, Jia T.

Mol Med Rep. 2015 Apr;11(4):2797-804. doi: 10.3892/mmr.2014.3071. Epub 2014 Dec 10.

PMID:
25504327
20.

Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.

Li W, Zhang Z, Guo L, Qiu T, Ling Y, Cao J, Guo H, Zhao H, Li L, Ying J.

Oncotarget. 2016 Feb 16;7(7):8332-40. doi: 10.18632/oncotarget.6671.

Supplemental Content

Support Center